ATE532073T1 - Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels - Google Patents
Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegelsInfo
- Publication number
- ATE532073T1 ATE532073T1 AT04765681T AT04765681T ATE532073T1 AT E532073 T1 ATE532073 T1 AT E532073T1 AT 04765681 T AT04765681 T AT 04765681T AT 04765681 T AT04765681 T AT 04765681T AT E532073 T1 ATE532073 T1 AT E532073T1
- Authority
- AT
- Austria
- Prior art keywords
- risk
- subject
- determining
- galectin
- thrombospondin
- Prior art date
Links
- 102000000802 Galectin 3 Human genes 0.000 title abstract 2
- 108010001517 Galectin 3 Proteins 0.000 title abstract 2
- 102100029529 Thrombospondin-2 Human genes 0.000 title abstract 2
- 108010060887 thrombospondin 2 Proteins 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title 1
- 239000003550 marker Substances 0.000 abstract 3
- 230000009787 cardiac fibrosis Effects 0.000 abstract 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/321—Arterial hypertension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078161A EP1522857A1 (en) | 2003-10-09 | 2003-10-09 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| PCT/EP2004/010879 WO2005040817A1 (en) | 2003-10-09 | 2004-09-27 | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE532073T1 true ATE532073T1 (de) | 2011-11-15 |
Family
ID=34306912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04765681T ATE532073T1 (de) | 2003-10-09 | 2004-09-27 | Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US7888137B2 (enExample) |
| EP (4) | EP1522857A1 (enExample) |
| JP (5) | JP4840744B2 (enExample) |
| CN (2) | CN1879022B (enExample) |
| AT (1) | ATE532073T1 (enExample) |
| AU (2) | AU2004284496C1 (enExample) |
| CA (2) | CA2842308A1 (enExample) |
| CY (2) | CY1112359T1 (enExample) |
| DK (2) | DK1682907T3 (enExample) |
| ES (2) | ES2530567T3 (enExample) |
| PL (2) | PL1682907T3 (enExample) |
| PT (2) | PT1682907E (enExample) |
| SI (2) | SI2317324T1 (enExample) |
| WO (1) | WO2005040817A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| AU2007301981A1 (en) * | 2006-09-25 | 2008-04-03 | Universiteit Maastricht | Means and methods for diagnosing and/or treating a subject at risk of developing heart failure |
| WO2008091948A2 (en) * | 2007-01-23 | 2008-07-31 | University Of Virginia Patent Foundation | Galectin-3-binding, protein as a biomarker of cardiovascular disease |
| CA2698899A1 (en) * | 2007-09-17 | 2009-03-26 | Bg Medicine, Inc. | Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione |
| CA2742265C (en) * | 2008-10-29 | 2014-07-15 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| EP2470911B1 (en) | 2009-08-25 | 2016-04-20 | BG Medicine, Inc. | Galectin-3 and cardiac resynchronization therapy |
| WO2012003475A1 (en) | 2010-07-02 | 2012-01-05 | Bg Medicine, Inc. | Statin therapy monitored by galectin- 3 measurement |
| US8703433B2 (en) * | 2010-10-18 | 2014-04-22 | Hideaki Hara | Marker for amyotrophic lateral sclerosis, and use thereof |
| EP2460890A1 (en) | 2010-12-01 | 2012-06-06 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases |
| EP2671080A1 (en) * | 2011-01-31 | 2013-12-11 | BG Medicine, Inc. | Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome |
| EP2686689B1 (en) | 2011-03-17 | 2019-08-07 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| AR086543A1 (es) * | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
| JP6276701B2 (ja) * | 2011-12-08 | 2018-02-07 | エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 血漿交換療法によるガレクチン−３レベルの低減 |
| EP2900267B1 (en) * | 2012-09-27 | 2019-05-15 | Siemens Healthcare Diagnostics Inc. | Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension |
| CA2926480A1 (en) * | 2012-11-15 | 2014-05-22 | Tufts University | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| AU2016207734A1 (en) | 2015-01-18 | 2017-08-03 | Diasorin S.P.A. | Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker |
| US10688565B2 (en) * | 2015-05-28 | 2020-06-23 | Kyocera Corporation | Cutting tool |
| CN112553335A (zh) * | 2020-12-17 | 2021-03-26 | 核工业总医院 | 肾细胞癌生物标志物及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632901A (en) * | 1984-05-11 | 1986-12-30 | Hybritech Incorporated | Method and apparatus for immunoassays |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| AU2684488A (en) * | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
| US6319676B1 (en) * | 1995-05-02 | 2001-11-20 | Carter Wallace, Inc. | Diagnostic detection device and method |
| BE1010935A7 (nl) * | 1997-02-19 | 1999-03-02 | Delanghe Joris Richard Siegfri | Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen. |
| US6210976B1 (en) * | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| US20060166276A1 (en) * | 1997-09-05 | 2006-07-27 | Lung Health Diagnostics Pty Ltd | Method of diagnosis and agents useful for same |
| IL134880A0 (en) * | 1997-09-05 | 2001-05-20 | Univ Southern Australia | A method of diagnosis |
| AU751660B2 (en) * | 1997-10-24 | 2002-08-22 | Shionogi & Co., Ltd. | Method for inhibiting decomposition of natriuretic peptides and improved method for assaying natriuretic peptides with the use of the same |
| WO1999051260A2 (en) * | 1998-04-02 | 1999-10-14 | Genentech, Inc. | Treatment of cardiac hypertrophy |
| CA2359667C (en) * | 1999-01-29 | 2009-10-20 | Roche Diagnostics Gmbh | Method of identifying n-terminal probnp |
| AU3704500A (en) * | 1999-02-19 | 2001-01-22 | University Of Iowa Research Foundation, The | Diagnostics and therapeutics for arterial wall disruptive disorders |
| JP2003507076A (ja) * | 1999-08-20 | 2003-02-25 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５ |
| US20020081590A1 (en) | 2000-02-04 | 2002-06-27 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| EP1358347A2 (en) | 2000-04-05 | 2003-11-05 | Incyte Genomics, Inc. | Genes expressed in foam cell differentiation |
| KR100395254B1 (ko) * | 2000-10-30 | 2003-08-21 | (주)자리타 바이오텍 | 종양 발생 예측 키트 |
| US7432060B2 (en) * | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
| AU2002220266A1 (en) * | 2000-11-09 | 2002-05-21 | Millennium Pharmaceuticals, Inc. | Methods for the identification and the treatment of cardiovascular disease |
| DE60144493D1 (de) * | 2000-12-08 | 2011-06-01 | Curagen Corp | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen |
| JP4035562B2 (ja) * | 2001-01-31 | 2008-01-23 | 国立大学法人富山大学 | ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット |
| WO2002074911A2 (en) | 2001-03-19 | 2002-09-26 | Wisconsin Alumni Research Foundation | Identification of gene expression alterations underlying the aging process in mammals |
| US20060019235A1 (en) | 2001-07-02 | 2006-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Molecular and functional profiling using a cellular microarray |
| US7447594B2 (en) | 2001-07-10 | 2008-11-04 | Ocimum Biosolutions, Inc. | Molecular cardiotoxicology modeling |
| US20030099958A1 (en) * | 2001-09-05 | 2003-05-29 | Vitivity, Inc. | Diagnosis and treatment of vascular disease |
| GB0124145D0 (en) | 2001-10-08 | 2001-11-28 | Bayer Ag | Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease |
| US20060141493A1 (en) | 2001-11-09 | 2006-06-29 | Duke University Office Of Science And Technology | Atherosclerotic phenotype determinative genes and methods for using the same |
| US7294652B2 (en) * | 2002-05-13 | 2007-11-13 | Arexis Ab | Autoimmune conditions and NADPH oxidase defects |
| AU2003290537A1 (en) | 2002-10-24 | 2004-05-13 | Duke University | Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications |
| BR0316111A (pt) | 2002-11-21 | 2005-09-13 | Wyeth Corp | Métodos para diagnosticar rcc e outros tumores sólidos |
| EP1431399A1 (en) * | 2002-12-20 | 2004-06-23 | Clinigenetics | Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions |
| US6889083B2 (en) * | 2003-04-21 | 2005-05-03 | Medtronic, Inc. | Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes |
| WO2005020784A2 (en) | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| WO2004111654A2 (en) | 2003-06-06 | 2004-12-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in ischaemic heart disease |
| US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| EP1560025A3 (en) * | 2003-10-03 | 2011-09-07 | F. Hoffmann-La Roche AG | Specific markers for diabetes |
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| DE10347436B4 (de) * | 2003-10-13 | 2007-08-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP) |
| EP1720562A4 (en) | 2004-01-15 | 2009-10-28 | Scios Inc | METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE |
| WO2006026074A2 (en) | 2004-08-04 | 2006-03-09 | Duke University | Atherosclerotic phenotype determinative genes and methods for using the same |
| AU2006210794A1 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Biomarkers for tissue status |
| US20070092886A1 (en) | 2005-03-22 | 2007-04-26 | Raymond Tabibiazar | Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease |
| US7632634B2 (en) | 2005-04-15 | 2009-12-15 | University Of Maryland Biotechnology Institute | Method and assay for early diagnosis of prostate cancer |
| US9592970B2 (en) * | 2008-07-17 | 2017-03-14 | Toby D. Henderson | Robotic gantry with end effector for product lifting |
| CA2742265C (en) * | 2008-10-29 | 2014-07-15 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| EP2470911B1 (en) * | 2009-08-25 | 2016-04-20 | BG Medicine, Inc. | Galectin-3 and cardiac resynchronization therapy |
-
2003
- 2003-10-09 EP EP03078161A patent/EP1522857A1/en not_active Withdrawn
-
2004
- 2004-09-27 CN CN2004800332637A patent/CN1879022B/zh not_active Expired - Fee Related
- 2004-09-27 SI SI200432221T patent/SI2317324T1/sl unknown
- 2004-09-27 PL PL04765681T patent/PL1682907T3/pl unknown
- 2004-09-27 SI SI200431813T patent/SI1682907T1/sl unknown
- 2004-09-27 AU AU2004284496A patent/AU2004284496C1/en not_active Ceased
- 2004-09-27 CA CA2842308A patent/CA2842308A1/en not_active Abandoned
- 2004-09-27 EP EP10186331.4A patent/EP2317324B1/en not_active Expired - Lifetime
- 2004-09-27 DK DK04765681.4T patent/DK1682907T3/da active
- 2004-09-27 PT PT04765681T patent/PT1682907E/pt unknown
- 2004-09-27 CN CN201210321227.7A patent/CN102998458B/zh not_active Expired - Fee Related
- 2004-09-27 ES ES10186331T patent/ES2530567T3/es not_active Expired - Lifetime
- 2004-09-27 AT AT04765681T patent/ATE532073T1/de active
- 2004-09-27 ES ES04765681T patent/ES2377012T3/es not_active Expired - Lifetime
- 2004-09-27 US US10/575,745 patent/US7888137B2/en active Active
- 2004-09-27 PL PL10186331T patent/PL2317324T3/pl unknown
- 2004-09-27 CA CA2542033A patent/CA2542033C/en not_active Expired - Lifetime
- 2004-09-27 EP EP04765681A patent/EP1682907B1/en not_active Expired - Lifetime
- 2004-09-27 EP EP14192739.2A patent/EP2919012A1/en not_active Withdrawn
- 2004-09-27 PT PT101863314T patent/PT2317324E/pt unknown
- 2004-09-27 DK DK10186331.4T patent/DK2317324T3/en active
- 2004-09-27 WO PCT/EP2004/010879 patent/WO2005040817A1/en not_active Ceased
- 2004-09-27 JP JP2006530040A patent/JP4840744B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-19 AU AU2009227844A patent/AU2009227844B2/en not_active Ceased
-
2010
- 2010-07-26 JP JP2010167334A patent/JP2010279378A/ja not_active Withdrawn
- 2010-10-28 US US12/914,329 patent/US8084276B2/en not_active Expired - Fee Related
-
2011
- 2011-04-12 JP JP2011088342A patent/JP5580774B2/ja not_active Expired - Lifetime
- 2011-11-23 US US13/304,145 patent/US20120220532A1/en not_active Abandoned
-
2012
- 2012-02-01 CY CY20121100108T patent/CY1112359T1/el unknown
-
2013
- 2013-03-08 US US13/791,350 patent/US20130189716A1/en not_active Abandoned
-
2014
- 2014-02-06 JP JP2014021394A patent/JP5789009B2/ja not_active Expired - Lifetime
- 2014-05-05 US US14/269,707 patent/US20150037353A1/en not_active Abandoned
-
2015
- 2015-02-12 CY CY20151100136T patent/CY1116147T1/el unknown
- 2015-04-13 JP JP2015081540A patent/JP2015171365A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE532073T1 (de) | Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels | |
| DE60327354D1 (de) | Diagnostischer assay zur bestimmung einer zellvermittelten immunantwort | |
| DE60041355D1 (de) | Verfahren zur detektion von erkrankungen | |
| ATE319093T1 (de) | Verfahren zur diagnose von leberkrankheit unter verwendung von biochemischen merkmalen | |
| ATE459578T1 (de) | Entsalzungsschiff sowie verfahren zur herstellung von entsalztem wasser | |
| ATE458201T1 (de) | Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6 | |
| DE3882058D1 (de) | Immunoreaktives reagens, verfahren zu seiner herstellung und seine verwendung zur bestimmung einer immunoreaktiven spezies. | |
| DE60033380D1 (de) | Verfahren zur quantifizierung der zahl von leukozyten in einer blutprobe | |
| DE60217351D1 (de) | Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens | |
| DE602005015140D1 (de) | Verfahren zur Bestimmung einer anfänglichen Nukleinsäurekonzentration anhand von Echtzeit-Nukleinsäure-Verstärkungsdaten | |
| DE60335276D1 (de) | Verfahren zur umrechnung von venösen blutwerten in arterielle blutwerte, system zur verwendung der methode | |
| DE59009364D1 (de) | Verfahren zur quantitativen Bestimmung zumindest eines chemischen Parameters eines Probenmediums. | |
| ATE482398T1 (de) | Verfahren zur stratifizierung von herzinsuffizienz | |
| DE60020347D1 (de) | Verfahren zur herstellung einer matrize von chemischen oder biologischen molekülsequenzen für eine chemische oder biologische analysevorrichtung | |
| EP1669761A3 (de) | Verfahren zur automatischen Bestimmung des endogenen Thrombinpotenzials | |
| ATE323282T1 (de) | VERFAHREN ZUR BESTIMMUNG EINES ERHÖHTEN RISIKOS EINER FRAU, EIN FOETUS MIT DEM ßDOWN-SYNDROMß ZU TRAGEN | |
| ATE423310T1 (de) | Verfahren und mittel zur bestimmung von gesamtsäure | |
| EP1605260A3 (de) | Verfahren und Testkit zur Bestimmung des organisch gebundenen Kohlenstoffs (TOC) | |
| ATE465411T1 (de) | Verfahren zur bestimmung von anfälligkeit einer person zur infektion | |
| ATE470154T1 (de) | Verfahren zur bewertung von insulinresistenz | |
| DE50312755D1 (de) | Verfahren zur Bestimmung des Verschleisses eines elektrochemischen Energiespeichers | |
| DE602006013201D1 (de) | Verfahren zur bewertung der nierenfunktion einer k | |
| RU2003134132A (ru) | Способ экспресс-определения кальция в моче | |
| ATE509277T1 (de) | Verfahren zur bestimmung von 1,5-anhydroglucitol unter verwendung von vollblut | |
| TELFORD et al. | Diatom Applications |